Obesity Pillars最新文献_第4页

Optimizing GLP-1 therapies for obesity and diabetes management 优化GLP-1治疗肥胖和糖尿病的方法

Obesity Pillars

Pub Date : 2025-10-24 DOI: 10.1016/j.obpill.2025.100222

Jarvis C. Noronha , Luc F. Van Gaal , Ian J. Neeland , Angela Fitch , Andreas FH. Pfeiffer , Laura Chiavaroli , Cyril WC. Kendall , John L. Sievenpiper

Background

Glucagon-like peptide-1 (GLP-1) therapies are highly effective for weight loss and metabolic improvement in obesity and type 2 diabetes management. However, their use poses clinical challenges, including loss of lean muscle mass and gastrointestinal side effects, both of which may affect adherence and long-term outcomes.

Methods

This commentary synthesizes current evidence and expert perspectives, drawing on presentations from the 42nd International Symposium on Diabetes and Nutrition by the Diabetes and Nutrition Study Group, to develop practical recommendations for integrating nutrition and physical activity with GLP-1 therapies for obesity and diabetes management.

Results

We summarize consensus recommendations from a global working group, organized into seven thematic modules, to guide alignment of GLP-1 therapies with dietary and lifestyle interventions across the key stages of the weight management journey. Evidence from several clinical trials demonstrate that the combination of GLP-1 therapies with structured dietary and exercise interventions results in additive weight loss effects compared with either strategy alone. Strategies to preserve lean mass with GLP-1 therapies include achieving protein intakes >1.2 g/kg/day, evenly distributed across meals, combined with aerobic activity and structured resistance training. Specific recommendations are provided to minimize nausea, vomiting, diarrhea, and constipation associated with GLP-1 therapies, as well as to prevent and manage complications such as, cholelithiasis and gastroesophageal reflux disease. Future research priorities include examining the impact of GLP-1 therapies on dietary habits and physical activity levels, improving muscle health assessment, and testing pharmacologic adjuncts to limit lean mass loss.

Conclusion

Maximizing the benefits of GLP-1 therapies require a multidisciplinary approach that integrates evidence-based nutrition, physical activity, and proactive management of gastrointestinal side effects. Such an approach can enhance adherence, preserve functional capacity, and sustain the long-term benefits of these therapies.

胰高血糖素样肽-1 （GLP-1）治疗对于肥胖和2型糖尿病患者的减肥和代谢改善非常有效。然而，它们的使用带来了临床挑战，包括瘦肌肉量的减少和胃肠道副作用，这两者都可能影响依从性和长期疗效。方法：本文综合了目前的证据和专家的观点，借鉴了糖尿病和营养研究小组在第42届糖尿病和营养国际研讨会上的演讲，提出了将营养和体育活动与GLP-1治疗结合起来治疗肥胖和糖尿病的实用建议。我们总结了全球工作组的共识建议，分为七个主题模块，以指导在体重管理过程的关键阶段将GLP-1治疗与饮食和生活方式干预相结合。来自几个临床试验的证据表明，与单独使用任何一种策略相比，GLP-1治疗与有组织的饮食和运动干预相结合会产生附加的减肥效果。通过GLP-1疗法保持瘦体重的策略包括实现蛋白质摄入量1.2 g/kg/天，均匀分布在每餐中，结合有氧运动和结构化阻力训练。提供了具体的建议，以尽量减少与GLP-1治疗相关的恶心、呕吐、腹泻和便秘，以及预防和管理并发症，如胆石症和胃食管反流病。未来的研究重点包括检查GLP-1疗法对饮食习惯和身体活动水平的影响，改善肌肉健康评估，以及测试药物辅助物以限制瘦体重损失。结论：要使GLP-1治疗的益处最大化，需要多学科的方法，将循证营养、身体活动和胃肠道副作用的积极管理结合起来。这种方法可以增强依从性，保持功能能力，并维持这些疗法的长期益处。

{"title":"Optimizing GLP-1 therapies for obesity and diabetes management","authors":"Jarvis C. Noronha , Luc F. Van Gaal , Ian J. Neeland , Angela Fitch , Andreas FH. Pfeiffer , Laura Chiavaroli , Cyril WC. Kendall , John L. Sievenpiper","doi":"10.1016/j.obpill.2025.100222","DOIUrl":"10.1016/j.obpill.2025.100222","url":null,"abstract":"<div><h3>Background</h3><div>Glucagon-like peptide-1 (GLP-1) therapies are highly effective for weight loss and metabolic improvement in obesity and type 2 diabetes management. However, their use poses clinical challenges, including loss of lean muscle mass and gastrointestinal side effects, both of which may affect adherence and long-term outcomes.</div></div><div><h3>Methods</h3><div>This commentary synthesizes current evidence and expert perspectives, drawing on presentations from the 42nd International Symposium on Diabetes and Nutrition by the Diabetes and Nutrition Study Group, to develop practical recommendations for integrating nutrition and physical activity with GLP-1 therapies for obesity and diabetes management.</div></div><div><h3>Results</h3><div>We summarize consensus recommendations from a global working group, organized into seven thematic modules, to guide alignment of GLP-1 therapies with dietary and lifestyle interventions across the key stages of the weight management journey. Evidence from several clinical trials demonstrate that the combination of GLP-1 therapies with structured dietary and exercise interventions results in additive weight loss effects compared with either strategy alone. Strategies to preserve lean mass with GLP-1 therapies include achieving protein intakes >1.2 g/kg/day, evenly distributed across meals, combined with aerobic activity and structured resistance training. Specific recommendations are provided to minimize nausea, vomiting, diarrhea, and constipation associated with GLP-1 therapies, as well as to prevent and manage complications such as, cholelithiasis and gastroesophageal reflux disease. Future research priorities include examining the impact of GLP-1 therapies on dietary habits and physical activity levels, improving muscle health assessment, and testing pharmacologic adjuncts to limit lean mass loss.</div></div><div><h3>Conclusion</h3><div>Maximizing the benefits of GLP-1 therapies require a multidisciplinary approach that integrates evidence-based nutrition, physical activity, and proactive management of gastrointestinal side effects. Such an approach can enhance adherence, preserve functional capacity, and sustain the long-term benefits of these therapies.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"16 ","pages":"Article 100222"},"PeriodicalIF":0.0,"publicationDate":"2025-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145528505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report 替西帕肽在同居伴侣中的替代疗效：一份观察性病例报告

Obesity Pillars

Pub Date : 2025-10-21 DOI: 10.1016/j.obpill.2025.100219

Kieran Eason , Claire Feeney , Tim Killeen

Introduction

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, produces substantial weight loss and glycaemic improvement in people with and without type 2 diabetes mellitus (T2DM). Obesity pharmacotherapy may influence household behaviours and indirectly affect untreated cohabitants, but no prior report has described such an effect.

Patient main concerns and findings

A cohabiting couple presented with obesity. The female partner (Patient A; no diabetes) sought weight loss therapy; the male partner (Patient B) had long-standing T2DM managed with insulin. Both partners were motivated to lose weight but had previously been unsuccessful through diet alone.

Primary diagnoses interventions and outcomes

Patient A began tirzepatide through a pharmacy-supervised weight management programme (escalated to 5 mg weekly). Patient B did not receive any pharmacotherapy but lived in the same household. Over 32 weeks, Patient A lost >30 % of baseline weight. Patient B lost 13 % of baseline weight, HbA1c fell from 9.5 % to 6.1 %, and insulin requirements declined by approximately 70 %. These outcomes paralleled those reported in tirzepatide clinical trials despite absence of medication in Patient B.

Conclusion

This case illustrates potential household-level or “vicarious” efficacy of anti-obesity pharmacotherapy. Environmental and behavioural changes in one partner may yield indirect metabolic benefits for untreated cohabitants. Recognition of such effects could inform patient counselling, cost-effectiveness assessments, and future research into family-based obesity care.

tirzepatide是一种双葡萄糖依赖性胰岛素性多肽（GIP）和胰高血糖素样肽-1 （GLP-1）受体激动剂，对2型糖尿病（T2DM）患者和非2型糖尿病患者都能产生显著的体重减轻和血糖改善。肥胖药物治疗可能影响家庭行为，并间接影响未治疗的同居者，但之前没有报道描述这种影响。一对同居夫妇表现为肥胖。女性伴侣（患者A，无糖尿病）寻求减肥治疗；男性伴侣（患者B）长期患有T2DM，并使用胰岛素治疗。这对伴侣都有减肥的动机，但之前仅仅通过节食都没有成功。初步诊断干预和结果：患者A通过药房监督的体重管理计划开始使用替西帕肽（每周5毫克）。病人B虽未接受任何药物治疗，但仍住在同一户人家。32周后，患者A的体重下降了基线体重的30%。患者B减轻了基线体重的13%，HbA1c从9.5%下降到6.1%，胰岛素需求下降了大约70%。这些结果与在替西帕肽临床试验中报道的结果相似，尽管患者b没有用药。结论该病例说明了抗肥胖药物治疗的潜在家庭水平或“替代”疗效。其中一方的环境和行为改变可能对未治疗的同居伴侣产生间接的代谢益处。认识到这些影响可以为患者咨询、成本效益评估和未来以家庭为基础的肥胖护理研究提供信息。

{"title":"Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report","authors":"Kieran Eason , Claire Feeney , Tim Killeen","doi":"10.1016/j.obpill.2025.100219","DOIUrl":"10.1016/j.obpill.2025.100219","url":null,"abstract":"<div><h3>Introduction</h3><div>Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, produces substantial weight loss and glycaemic improvement in people with and without type 2 diabetes mellitus (T2DM). Obesity pharmacotherapy may influence household behaviours and indirectly affect untreated cohabitants, but no prior report has described such an effect.</div></div><div><h3>Patient main concerns and findings</h3><div>A cohabiting couple presented with obesity. The female partner (Patient A; no diabetes) sought weight loss therapy; the male partner (Patient B) had long-standing T2DM managed with insulin. Both partners were motivated to lose weight but had previously been unsuccessful through diet alone.</div></div><div><h3>Primary diagnoses interventions and outcomes</h3><div>Patient A began tirzepatide through a pharmacy-supervised weight management programme (escalated to 5 mg weekly). Patient B did not receive any pharmacotherapy but lived in the same household. Over 32 weeks, Patient A lost >30 % of baseline weight. Patient B lost 13 % of baseline weight, HbA1c fell from 9.5 % to 6.1 %, and insulin requirements declined by approximately 70 %. These outcomes paralleled those reported in tirzepatide clinical trials despite absence of medication in Patient B.</div></div><div><h3>Conclusion</h3><div>This case illustrates potential household-level or “vicarious” efficacy of anti-obesity pharmacotherapy. Environmental and behavioural changes in one partner may yield indirect metabolic benefits for untreated cohabitants. Recognition of such effects could inform patient counselling, cost-effectiveness assessments, and future research into family-based obesity care.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"16 ","pages":"Article 100219"},"PeriodicalIF":0.0,"publicationDate":"2025-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145361964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: The ELECT extension study 长期使用口服可变形高吸收水凝胶胶囊减肥的安全性和有效性：ELECT扩展研究

Obesity Pillars

Pub Date : 2025-10-20 DOI: 10.1016/j.obpill.2025.100216

Moshe Kamar , Donna H. Ryan , Sharon Leonard , Holly R. Wyatt , Yael Kenan , Liora Cohen Asaraf , Eti Ganon-Elazar , Jamy D. Ard

Background

Long-term weight-loss maintenance remains challenging despite of the numerous available treatments. The previously published pivotal randomized RESET study demonstrated a mean weight reduction from baseline of 6.6 % with Epitomee and a mean weight reduction of 4.6 % with placebo (p < 0.001). In this study we investigated the efficacy and safety of the extended use of Epitomee, an FDA cleared, non-pharmacological treatment for weight management.

Methods

In this open label extension study, a subset of participants in the RESET study who lost ≥3 % of initial body weight during a 24-week treatment with Epitomee capsule or placebo, as an adjunct to lifestyle counseling, were eligible for a 24-week open-label extension study (ELECT).

Results

Continuous treatment with Epitomee and lifestyle counseling for 48 weeks was associated with sustained reduction in body weight of 11.2 ± 8.4 % (p < 0.001) and sustained prior improvements in cardiometabolic risk factors and quality of life (QOL). Taking the Epitomee capsule for 24 weeks, after previous weight loss with the placebo treatment, was associated with an additional 1.5 ± 4.2 % weight loss, yielding a total 7.5 ± 5.5 % reduction at 48 weeks and additional improvements in QOL. Capsule adherence exceeded 94 %. Extended use of Epitomee had a favorable safety profile, with no serious adverse device-related events and no discontinuation due to adverse events.

Conclusions

In this open-label study, extended use of Epitomee, combined with lifestyle counseling, was associated with maintenance of prior weight loss and favorable safety profile (NCT04994769).

背景：尽管有许多可用的治疗方法，长期减肥维持仍然具有挑战性。先前发表的关键随机RESET研究表明，与基线相比，Epitomee的平均体重减轻了6.6%，安慰剂的平均体重减轻了4.6% （p < 0.001）。在这项研究中，我们调查了延长使用Epitomee的有效性和安全性，这是一种FDA批准的非药物治疗体重管理方法。方法：在这项开放标签扩展研究中，RESET研究的一部分参与者在接受24周的Epitomee胶囊或安慰剂治疗期间减轻了≥3%的初始体重，作为生活方式咨询的辅助治疗，有资格参加24周的开放标签扩展研究（ELECT）。结果持续使用Epitomee和生活方式咨询治疗48周，体重持续下降11.2±8.4% (p < 0.001)，心脏代谢危险因素和生活质量（QOL）持续改善。在先前使用安慰剂治疗体重减轻后，服用Epitomee胶囊24周，与额外的1.5±4.2%体重减轻相关，在48周时总共减少7.5±5.5%，并进一步改善生活质量。胶囊依从性超过94%。长期使用Epitomee具有良好的安全性，没有与器械相关的严重不良事件，也没有因不良事件而停药。结论：在这项开放标签研究中，延长使用Epitomee并结合生活方式咨询，与维持既往体重减轻和良好的安全性相关（NCT04994769）。

{"title":"The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: The ELECT extension study","authors":"Moshe Kamar , Donna H. Ryan , Sharon Leonard , Holly R. Wyatt , Yael Kenan , Liora Cohen Asaraf , Eti Ganon-Elazar , Jamy D. Ard","doi":"10.1016/j.obpill.2025.100216","DOIUrl":"10.1016/j.obpill.2025.100216","url":null,"abstract":"<div><h3>Background</h3><div>Long-term weight-loss maintenance remains challenging despite of the numerous available treatments. The previously published pivotal randomized RESET study demonstrated a mean weight reduction from baseline of 6.6 % with Epitomee and a mean weight reduction of 4.6 % with placebo (p < 0.001). In this study we investigated the efficacy and safety of the extended use of Epitomee, an FDA cleared, non-pharmacological treatment for weight management.</div></div><div><h3>Methods</h3><div>In this open label extension study, a subset of participants in the RESET study who lost ≥3 % of initial body weight during a 24-week treatment with Epitomee capsule or placebo, as an adjunct to lifestyle counseling, were eligible for a 24-week open-label extension study (ELECT).</div></div><div><h3>Results</h3><div>Continuous treatment with Epitomee and lifestyle counseling for 48 weeks was associated with sustained reduction in body weight of 11.2 ± 8.4 % (p < 0.001) and sustained prior improvements in cardiometabolic risk factors and quality of life (QOL). Taking the Epitomee capsule for 24 weeks, after previous weight loss with the placebo treatment, was associated with an additional 1.5 ± 4.2 % weight loss, yielding a total 7.5 ± 5.5 % reduction at 48 weeks and additional improvements in QOL. Capsule adherence exceeded 94 %. Extended use of Epitomee had a favorable safety profile, with no serious adverse device-related events and no discontinuation due to adverse events.</div></div><div><h3>Conclusions</h3><div>In this open-label study, extended use of Epitomee, combined with lifestyle counseling, was associated with maintenance of prior weight loss and favorable safety profile (NCT04994769).</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"16 ","pages":"Article 100216"},"PeriodicalIF":0.0,"publicationDate":"2025-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145424615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to Letter to the Editor 对给编辑的信的回应

Obesity Pillars

Pub Date : 2025-10-08 DOI: 10.1016/j.obpill.2025.100215

引用次数: 0

Exploring the role of digital health technologies in assessing functional mobility and physical activity: Insights from qualitative interviews in adults with obesity or overweight 探索数字健康技术在评估功能流动性和身体活动中的作用：来自肥胖或超重成人定性访谈的见解

Obesity Pillars

Pub Date : 2025-10-01 DOI: 10.1016/j.obpill.2025.100214

Jeremiah J. Trudeau , Brian Winger , Theresa Hunter Gibble , Lisa M. Neff , Chris Marshall , Chloe Carmichael , Daniel M. Ford , Elizabeth Collins

Background

Digital health technologies (DHTs) offer passive, objective, and continuous monitoring of difficult-to-report mobility-related behaviors like physical activity (PA) and functional mobility (FM), which are important concepts of interest in obesity-related clinical studies. This study was conducted to identify which aspects of FM/PA are meaningful to people living with obesity or overweight and establish how those concepts can be measured by passive monitoring using DHTs.

Methods

Qualitative concept elicitation interviews were conducted among 4 groups of adults (≥18 years) with obesity (body mass index [BMI] ≥30 kg/m²) and no obesity-related complications, overweight (BMI ≥27 kg/m²) with type 2 diabetes, overweight with obstructive sleep apnea, and overweight with lower-limb osteoarthritis. Two rounds of interviews were conducted to first identify the most important concepts of interest relating to FM/PA and then determine what level of change in FM and PA would be considered meaningful and important in the context of obesity treatment.

Results

A total of 48 participants were recruited for Round 1 (n = 24) and Round 2 (n = 24). The most frequently reported concepts of interest identified for FM and PA were walking on a flat surface, moderate-to-vigorous physical activity (MVPA), climbing stairs, walking uphill, and standing. All four most frequently reported concepts of FM/PA in Round 1 (MVPA, going up stairs, walking, and standing) were also considered relevant and bothersome in Round 2. The majority of the participants confirmed that measuring step count and changes in minutes of MVPA would be meaningful for them with respect to treatment for obesity.

Conclusion

People with obesity or overweight reported the ability to perform MVPA, going up stairs, walking, and standing as meaningful FM/PA outcomes. DHTs have the potential to provide relevant information about the functional status of people with obesity and could be more frequently implemented in obesity treatment studies and clinical practice.

数字健康技术（dht）提供被动、客观和持续的监测难以报告的活动相关行为，如身体活动（PA）和功能活动（FM），这是肥胖相关临床研究的重要概念。本研究旨在确定FM/PA的哪些方面对肥胖或超重人群有意义，并确定如何通过使用dht进行被动监测来测量这些概念。方法采用定性概念启发访谈法，对4组肥胖（体重指数[BMI]≥30 kg/m2）且无肥胖相关并发症、超重（BMI≥27 kg/m2）合并2型糖尿病、超重合并阻塞性睡眠呼吸暂停、超重合并下肢骨关节炎的成年人（≥18岁）进行问卷调查。进行了两轮访谈，首先确定与FM/PA相关的最重要的概念，然后确定FM和PA的变化水平在肥胖治疗的背景下被认为是有意义和重要的。结果第1轮（n = 24）和第2轮（n = 24）共招募48名受试者。FM和PA最常被报道的兴趣概念是在平面上行走、中等到剧烈的身体活动（MVPA）、爬楼梯、爬山和站立。在第1轮中，FM/PA的所有四个最常被报道的概念（MVPA、上楼、行走和站立）在第2轮中也被认为是相关的和麻烦的。大多数参与者确认，测量步数和MVPA的分钟变化对他们来说对于治疗肥胖是有意义的。结论肥胖或超重的人报告MVPA、上楼、行走和站立的能力是有意义的FM/PA结果。dht有可能提供有关肥胖患者功能状态的相关信息，并且可以更频繁地在肥胖治疗研究和临床实践中实施。

{"title":"Exploring the role of digital health technologies in assessing functional mobility and physical activity: Insights from qualitative interviews in adults with obesity or overweight","authors":"Jeremiah J. Trudeau , Brian Winger , Theresa Hunter Gibble , Lisa M. Neff , Chris Marshall , Chloe Carmichael , Daniel M. Ford , Elizabeth Collins","doi":"10.1016/j.obpill.2025.100214","DOIUrl":"10.1016/j.obpill.2025.100214","url":null,"abstract":"<div><h3>Background</h3><div>Digital health technologies (DHTs) offer passive, objective, and continuous monitoring of difficult-to-report mobility-related behaviors like physical activity (PA) and functional mobility (FM), which are important concepts of interest in obesity-related clinical studies. This study was conducted to identify which aspects of FM/PA are meaningful to people living with obesity or overweight and establish how those concepts can be measured by passive monitoring using DHTs.</div></div><div><h3>Methods</h3><div>Qualitative concept elicitation interviews were conducted among 4 groups of adults (≥18 years) with obesity (body mass index [BMI] ≥30 kg/m<sup>2</sup>) and no obesity-related complications, overweight (BMI ≥27 kg/m<sup>2</sup>) with type 2 diabetes, overweight with obstructive sleep apnea, and overweight with lower-limb osteoarthritis. Two rounds of interviews were conducted to first identify the most important concepts of interest relating to FM/PA and then determine what level of change in FM and PA would be considered meaningful and important in the context of obesity treatment.</div></div><div><h3>Results</h3><div>A total of 48 participants were recruited for Round 1 (n = 24) and Round 2 (n = 24). The most frequently reported concepts of interest identified for FM and PA were walking on a flat surface, moderate-to-vigorous physical activity (MVPA), climbing stairs, walking uphill, and standing. All four most frequently reported concepts of FM/PA in Round 1 (MVPA, going up stairs, walking, and standing) were also considered relevant and bothersome in Round 2. The majority of the participants confirmed that measuring step count and changes in minutes of MVPA would be meaningful for them with respect to treatment for obesity.</div></div><div><h3>Conclusion</h3><div>People with obesity or overweight reported the ability to perform MVPA, going up stairs, walking, and standing as meaningful FM/PA outcomes. DHTs have the potential to provide relevant information about the functional status of people with obesity and could be more frequently implemented in obesity treatment studies and clinical practice.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"16 ","pages":"Article 100214"},"PeriodicalIF":0.0,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Improving nutritional assessment in GLP-1RA therapy: Beyond self-reports to equitable interventions 改善GLP-1RA治疗中的营养评估：超越自我报告到公平干预

Obesity Pillars

Pub Date : 2025-09-30 DOI: 10.1016/j.obpill.2025.100213

Parth Aphale, Himanshu Shekhar, Shashank Dokania

引用次数: 0

Exploring the effects of high protein versus high fat snacks on satiety, gut hormones and insulin secretion in women with overweight and obesity: A randomized clinical trial 探索高蛋白和高脂肪零食对超重和肥胖女性饱腹感、肠道激素和胰岛素分泌的影响：一项随机临床试验

Obesity Pillars

Pub Date : 2025-09-27 DOI: 10.1016/j.obpill.2025.100212

Nahla Al-Bayyari , Maysoon Alhameedy , Razan Omoush , Hadeel Ghazzawi

Background

Nuts generally blunt the postprandial increases in glucose levels and increase satiety, while yogurt studies yield inconclusive results regarding post-meal hunger. This study investigated the effects of high-protein, and high-fat snacks, specifically Greek yogurt, and peanuts, on satiety, gut hormones, and insulin secretion in women with overweight and obesity. The hypothesis posited that peanuts would exhibit a more beneficial impact on satiety, gut hormones, and insulin levels compared to Greek yogurt.

Methods

The two-arm parallel randomized trial involved fifty participants aged 30–40 years with a BMI between 25 and 35 kg/m², randomly divided into peanut (n = 25) and Greek yogurt (n = 25) groups. After three days of adhering to 1200 Kcal diet, appetite sensations were gauged using a visual analog scale (VAS) upon arrival, and at 30- and 60-min post-snack. Pre- and post-snacking, plasma levels of cholecystokinin (CCK), Peptide Tyrosine-Tyrosine (PYY), Glucagon Like Peptide-1 (GLP-1), Ghrelin (GHRL), and insulin were analyzed.

Results

Revealed that Greek yogurt induced a statistically significant increase in satiety 30 min after consumption and markedly elevated postprandial insulin levels compared to peanuts. Moreover, notable intergroup differences in postprandial insulin concentrations were observed in the Greek yogurt group. The peanut group had no significant alterations in PYY, GLP-1, CCK or GHRL levels. Pre-snacking, GHRL levels exhibited a positive association with abdominal circumference, weight, and fat mass, while CCK levels displayed a negative association with abdominal circumference, weight, and fat mass.

Conclusion

Greek yogurt may enhance satiety and thus has the potential to positively influence body weight in individuals with overweight and/or obesity. Further research is required to elucidate appetite control mechanisms.

Trial registration

The study was registered on ClinicalTrials.gov (No. NCT 04518930).

坚果通常会减缓餐后葡萄糖水平的升高，增加饱腹感，而酸奶研究对餐后饥饿感的影响尚无定论。这项研究调查了高蛋白和高脂肪零食，特别是希腊酸奶和花生，对超重和肥胖女性的饱腹感、肠道激素和胰岛素分泌的影响。该假说认为，与希腊酸奶相比，花生对饱腹感、肠道激素和胰岛素水平的影响更有益。方法采用两组平行随机试验，年龄30 ~ 40岁，BMI在25 ~ 35 kg/m2之间，随机分为花生组（n = 25）和希腊酸奶组（n = 25）。在坚持1200千卡的饮食三天后，在到达时以及在零食后30和60分钟使用视觉模拟量表（VAS）测量食欲感觉。分析进食前后血浆中胆囊收缩素（CCK）、肽酪氨酸-酪氨酸（PYY）、胰高血糖素样肽-1 （GLP-1）、胃饥饿素（GHRL）和胰岛素的水平。结果显示，与花生相比，希腊酸奶在食用30分钟后诱导饱腹感显著增加，餐后胰岛素水平显著升高。此外，在希腊酸奶组中观察到餐后胰岛素浓度的显著组间差异。花生组PYY、GLP-1、CCK和GHRL水平无明显变化。吃零食前，GHRL水平与腹围、体重和脂肪量呈正相关，而CCK水平与腹围、体重和脂肪量呈负相关。结论：希腊酸奶可以提高饱腹感，因此对超重和/或肥胖个体的体重有积极影响。需要进一步的研究来阐明食欲控制机制。试验注册：该研究已在ClinicalTrials.gov （No. 5）上注册。NCT 04518930)。

{"title":"Exploring the effects of high protein versus high fat snacks on satiety, gut hormones and insulin secretion in women with overweight and obesity: A randomized clinical trial","authors":"Nahla Al-Bayyari , Maysoon Alhameedy , Razan Omoush , Hadeel Ghazzawi","doi":"10.1016/j.obpill.2025.100212","DOIUrl":"10.1016/j.obpill.2025.100212","url":null,"abstract":"<div><h3>Background</h3><div>Nuts generally blunt the postprandial increases in glucose levels and increase satiety, while yogurt studies yield inconclusive results regarding post-meal hunger. This study investigated the effects of high-protein, and high-fat snacks, specifically Greek yogurt, and peanuts, on satiety, gut hormones, and insulin secretion in women with overweight and obesity. The hypothesis posited that peanuts would exhibit a more beneficial impact on satiety, gut hormones, and insulin levels compared to Greek yogurt.</div></div><div><h3>Methods</h3><div>The two-arm parallel randomized trial involved fifty participants aged 30–40 years with a BMI between 25 and 35 kg/m<sup>2</sup>, randomly divided into peanut (n = 25) and Greek yogurt (n = 25) groups. After three days of adhering to 1200 Kcal diet, appetite sensations were gauged using a visual analog scale (VAS) upon arrival, and at 30- and 60-min post-snack. Pre- and post-snacking, plasma levels of cholecystokinin (CCK), Peptide Tyrosine-Tyrosine (PYY), Glucagon Like Peptide-1 (GLP-1), Ghrelin (GHRL), and insulin were analyzed.</div></div><div><h3>Results</h3><div>Revealed that Greek yogurt induced a statistically significant increase in satiety 30 min after consumption and markedly elevated postprandial insulin levels compared to peanuts. Moreover, notable intergroup differences in postprandial insulin concentrations were observed in the Greek yogurt group. The peanut group had no significant alterations in PYY, GLP-1, CCK or GHRL levels. Pre-snacking, GHRL levels exhibited a positive association with abdominal circumference, weight, and fat mass, while CCK levels displayed a negative association with abdominal circumference, weight, and fat mass.</div></div><div><h3>Conclusion</h3><div>Greek yogurt may enhance satiety and thus has the potential to positively influence body weight in individuals with overweight and/or obesity. Further research is required to elucidate appetite control mechanisms.</div></div><div><h3>Trial registration</h3><div>The study was registered on <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> (No. NCT 04518930).</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"16 ","pages":"Article 100212"},"PeriodicalIF":0.0,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145227026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Establishing a multidisciplinary bariatric arterial embolization program: A two-year clinical experience 建立一个多学科的减肥动脉栓塞计划：两年的临床经验

Obesity Pillars

Pub Date : 2025-09-25 DOI: 10.1016/j.obpill.2025.100211

Adham Khalil , Alan J. Kim , Lawrence J. Cheskin , Selvi Rajagopal , Bill Morefield , Zoobia Chaudhry , Kimberly A. Gudzune , Clifford R. Weiss

Background

Bariatric arterial embolization (BAE) is an emerging, minimally invasive, image-guided procedure for treating obesity in patients for whom nonoperative treatments have failed and metabolic-bariatric surgery is not an option. BAE has shown success in clinical studies, but guidance on integrating BAE into weight management programs (WMPs) is lacking. We describe our experience with building a multidisciplinary clinical program that integrates BAE into routine care for obesity.

Methods

We conducted a retrospective, single-center observational case series of patients treated with BAE through our WMP between November 2021 and September 2023. Patient chart review was performed for the following criteria for consideration of BAE: had a body mass index ≥30 kg/m², was unable to achieve weight and health goals through nonoperative management, and was ineligible or unwilling to undergo metabolic-bariatric surgery. Through multidisciplinary discussion, BAE was deemed suitable based on various patient-specific medical and technical reasons.

Results

Thirty-one patients were considered for BAE through the program. Of those, 9 patients were cleared for BAE and 5 patients (4 women and 1 man) eventually underwent BAE. The mean age of the embolized patients was 42 years (range: 28–56). The mean pre-procedure weight was 116 kg (range: 100–134). Patients achieved a mean total body weight loss of 7.0% at 4–5 months’ follow-up and 4.2% at 12 months. BAE was performed successfully with only transient nausea and vomiting postoperatively. The mean cost for BAE was $14,329 US dollars.

Conclusions

BAE offers an obesity treatment option with low complication risk and potential benefit when used as part of a comprehensive WMP. Close collaboration between interventional radiologists and obesity medicine physicians is key for success. BAE should be offered as a component within a comprehensive WMP rather than as a stand-alone procedure.

背景：减肥动脉栓塞（BAE）是一种新兴的、微创的、图像引导的治疗方法，用于治疗非手术治疗失败且不能选择代谢减肥手术的肥胖患者。BAE在临床研究中取得了成功，但目前缺乏将BAE整合到体重管理项目（wmp）中的指导。我们描述了我们建立一个多学科临床项目的经验，该项目将BAE整合到肥胖的常规护理中。方法：我们对2021年11月至2023年9月期间通过我们的WMP治疗的BAE患者进行了回顾性、单中心观察病例系列。根据以下标准对患者进行病历回顾，以考虑BAE：体重指数≥30 kg/m2，无法通过非手术管理实现体重和健康目标，不符合或不愿接受代谢减肥手术。通过多学科讨论，基于各种患者特定的医学和技术原因，认为BAE是合适的。结果31例患者通过该方案被考虑为BAE。其中9例患者清除了BAE， 5例患者（4女1男）最终接受了BAE。栓塞患者的平均年龄为42岁（范围28-56岁）。手术前平均体重为116公斤（范围：100-134）。在4-5个月的随访中，患者的平均总体重减轻了7.0%，在12个月的随访中减轻了4.2%。BAE手术成功，术后仅有短暂性恶心和呕吐。BAE的平均成本为14329美元。结论：bae作为综合WMP的一部分，提供了一种并发症风险低且潜在益处的肥胖治疗选择。介入放射科医师和肥胖医学医师之间的密切合作是成功的关键。BAE应该作为综合WMP中的一个组件提供，而不是作为一个独立的过程。

{"title":"Establishing a multidisciplinary bariatric arterial embolization program: A two-year clinical experience","authors":"Adham Khalil , Alan J. Kim , Lawrence J. Cheskin , Selvi Rajagopal , Bill Morefield , Zoobia Chaudhry , Kimberly A. Gudzune , Clifford R. Weiss","doi":"10.1016/j.obpill.2025.100211","DOIUrl":"10.1016/j.obpill.2025.100211","url":null,"abstract":"<div><h3>Background</h3><div>Bariatric arterial embolization (BAE) is an emerging, minimally invasive, image-guided procedure for treating obesity in patients for whom nonoperative treatments have failed and metabolic-bariatric surgery is not an option. BAE has shown success in clinical studies, but guidance on integrating BAE into weight management programs (WMPs) is lacking. We describe our experience with building a multidisciplinary clinical program that integrates BAE into routine care for obesity.</div></div><div><h3>Methods</h3><div>We conducted a retrospective, single-center observational case series of patients treated with BAE through our WMP between November 2021 and September 2023. Patient chart review was performed for the following criteria for consideration of BAE: had a body mass index ≥30 kg/m<sup>2</sup>, was unable to achieve weight and health goals through nonoperative management, and was ineligible or unwilling to undergo metabolic-bariatric surgery. Through multidisciplinary discussion, BAE was deemed suitable based on various patient-specific medical and technical reasons.</div></div><div><h3>Results</h3><div>Thirty-one patients were considered for BAE through the program. Of those, 9 patients were cleared for BAE and 5 patients (4 women and 1 man) eventually underwent BAE. The mean age of the embolized patients was 42 years (range: 28–56). The mean pre-procedure weight was 116 kg (range: 100–134). Patients achieved a mean total body weight loss of 7.0% at 4–5 months’ follow-up and 4.2% at 12 months. BAE was performed successfully with only transient nausea and vomiting postoperatively. The mean cost for BAE was $14,329 US dollars.</div></div><div><h3>Conclusions</h3><div>BAE offers an obesity treatment option with low complication risk and potential benefit when used as part of a comprehensive WMP. Close collaboration between interventional radiologists and obesity medicine physicians is key for success. BAE should be offered as a component within a comprehensive WMP rather than as a stand-alone procedure.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"16 ","pages":"Article 100211"},"PeriodicalIF":0.0,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145265495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Letters to the editor regarding the “Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society” 关于“支持GLP-1治疗肥胖的营养优先：美国生活方式医学院、美国营养学会、肥胖医学协会和肥胖学会的联合咨询”给编辑的信

Obesity Pillars

Pub Date : 2025-09-16 DOI: 10.1016/j.obpill.2025.100210

引用次数: 0

The impact of ultra-processed foods on pediatric health 超加工食品对儿童健康的影响

Obesity Pillars

Pub Date : 2025-09-09 DOI: 10.1016/j.obpill.2025.100203

Venkata Sushma Chamarthi , Pallavi Shirsat , Kunal Sonavane , Saketh Parsi , Usha Ravi , Harikrishna Choudary Ponnam , Shagun Bindlish , Evan P. Nadler , Rahul Kashyap , Sarah Ro

Introduction

Ultra-processed foods (UPFs) have become increasingly incorporated into pediatric diets, accounting for approximately 67 % of the total energy consumption in United States (US) children. Manufactured through industrial processing and enriched with excess sugars, unhealthy fats, and sodium, while lacking essential nutrients, UPFs present a substantial public health concern. We aimed to conduct a comprehensive review of the impact of UPFs on pediatric health.

Methods

We reviewed the effects of UPF on pediatric health using data from observational studies, systematic reviews, and policy reports. Our review explored the social, environmental, and economic drivers of UPF consumption, associated health consequences, and proposed mitigation strategies. We also examined National Health and Nutrition Examination Survey (NHANES) data, the 2025 US Dietary Guidelines Advisory Committee’s (USDA) report, and the Make America Healthy Again (MAHA) commission findings.

Results

UPF intake has dramatically increased during early childhood, with toddlers and school-aged children obtaining 47 % and 59.4 % of their daily calories, respectively, from UPFs. Higher consumption is linked to pediatric obesity, cardiometabolic risks such as insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD), mental health concerns, and gut microbiome disruption. Early-life exposure to UPFs can establish unhealthy dietary patterns that persist into adulthood, raising the risk of chronic disease. Greater UPF consumption is often observed among lower-income families, highlighting a key health disparity.

Conclusion

UPF consumption is a modifiable risk factor for non-communicable diseases in children. Addressing it requires urgent, coordinated action at multiple levels. Strategies include UPF and sugar-sweetened beverage screening during well-child visits, policy restrictions on food marketing, clearer nutrition labeling, healthier school meals, and personalized family-centered dietary counseling. Clinicians need standardized tools and training to counsel families effectively. Policy initiatives should prioritize prevention-focused measures to protect children's health.

超加工食品（upf）已越来越多地纳入儿科饮食，约占美国儿童总能量消耗的67%。upf是通过工业加工制造的，富含过量的糖、不健康的脂肪和钠，同时缺乏必要的营养素，是一个重大的公共卫生问题。我们的目的是对upf对儿科健康的影响进行全面审查。方法我们利用观察性研究、系统评价和政策报告的数据回顾了UPF对儿童健康的影响。我们的综述探讨了UPF消费的社会、环境和经济驱动因素、相关的健康后果，并提出了缓解策略。我们还检查了国家健康和营养检查调查（NHANES）的数据，2025年美国膳食指南咨询委员会（USDA）的报告，以及让美国再次健康（MAHA）委员会的调查结果。结果：在幼儿时期，supf的摄入量急剧增加，幼儿和学龄儿童分别从upf中获得47%和59.4%的每日卡路里。较高的消费量与儿童肥胖、心脏代谢风险（如胰岛素抵抗和代谢功能障碍相关的脂肪变性肝病（MASLD））、心理健康问题和肠道微生物群破坏有关。生命早期接触upf会形成不健康的饮食模式，并持续到成年，增加患慢性病的风险。在低收入家庭中经常观察到更多的UPF消费，突出了一个关键的健康差距。结论upf消费是儿童非传染性疾病可改变的危险因素。解决这一问题需要在多个层面采取紧急、协调的行动。策略包括在健康儿童访问期间进行UPF和含糖饮料筛查，对食品营销进行政策限制，更清晰的营养标签，更健康的学校膳食，以及个性化的以家庭为中心的饮食咨询。临床医生需要标准化的工具和培训来有效地为家庭提供咨询。政策举措应优先考虑以预防为重点的措施，以保护儿童健康。

{"title":"The impact of ultra-processed foods on pediatric health","authors":"Venkata Sushma Chamarthi , Pallavi Shirsat , Kunal Sonavane , Saketh Parsi , Usha Ravi , Harikrishna Choudary Ponnam , Shagun Bindlish , Evan P. Nadler , Rahul Kashyap , Sarah Ro","doi":"10.1016/j.obpill.2025.100203","DOIUrl":"10.1016/j.obpill.2025.100203","url":null,"abstract":"<div><h3>Introduction</h3><div>Ultra-processed foods (UPFs) have become increasingly incorporated into pediatric diets, accounting for approximately 67 % of the total energy consumption in United States (US) children. Manufactured through industrial processing and enriched with excess sugars, unhealthy fats, and sodium, while lacking essential nutrients, UPFs present a substantial public health concern. We aimed to conduct a comprehensive review of the impact of UPFs on pediatric health.</div></div><div><h3>Methods</h3><div>We reviewed the effects of UPF on pediatric health using data from observational studies, systematic reviews, and policy reports. Our review explored the social, environmental, and economic drivers of UPF consumption, associated health consequences, and proposed mitigation strategies. We also examined National Health and Nutrition Examination Survey (NHANES) data, the 2025 US Dietary Guidelines Advisory Committee’s (USDA) report, and the Make America Healthy Again (MAHA) commission findings.</div></div><div><h3>Results</h3><div>UPF intake has dramatically increased during early childhood, with toddlers and school-aged children obtaining 47 % and 59.4 % of their daily calories, respectively, from UPFs. Higher consumption is linked to pediatric obesity, cardiometabolic risks such as insulin resistance and metabolic dysfunction-associated steatotic liver disease (MASLD), mental health concerns, and gut microbiome disruption. Early-life exposure to UPFs can establish unhealthy dietary patterns that persist into adulthood, raising the risk of chronic disease. Greater UPF consumption is often observed among lower-income families, highlighting a key health disparity.</div></div><div><h3>Conclusion</h3><div>UPF consumption is a modifiable risk factor for non-communicable diseases in children. Addressing it requires urgent, coordinated action at multiple levels. Strategies include UPF and sugar-sweetened beverage screening during well-child visits, policy restrictions on food marketing, clearer nutrition labeling, healthier school meals, and personalized family-centered dietary counseling. Clinicians need standardized tools and training to counsel families effectively. Policy initiatives should prioritize prevention-focused measures to protect children's health.</div></div>","PeriodicalId":100977,"journal":{"name":"Obesity Pillars","volume":"16 ","pages":"Article 100203"},"PeriodicalIF":0.0,"publicationDate":"2025-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145048595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0